David Lorente
About
David Lorente is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, David Lorente has authored 100 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 34 papers in Cancer Research. Recurrent topics in David Lorente's work include Prostate Cancer Treatment and Research (63 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Cancer, Lipids, and Metabolism (18 papers). David Lorente is often cited by papers focused on Prostate Cancer Treatment and Research (63 papers), Radiopharmaceutical Chemistry and Applications (26 papers) and Cancer, Lipids, and Metabolism (18 papers). David Lorente collaborates with scholars based in Spain, United Kingdom and United States. David Lorente's co-authors include Johann S. de Bono, Aurelius Omlin, Gerhardt Attard, Joaquı́n Mateo, Roberta Ferraldeschi, Diletta Bianchini, David Olmos, Carmel Pezaro, Zafeiris Zafeiriou and Raquel Pérez-López and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
David Lorente
94 papers receiving 2.8k citations
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| David Lorente | 1.8k | 1.2k | 1.1k | 653 | 594 | 100 | 2.9k | |
| Michael T. Schweizer | 2.2k 1.2× | 1.1k 0.9× | 746 0.7× | 444 0.7× | 929 1.6× | 144 | 3.1k | |
| Ivo Kocák | 2.5k 1.3× | 1.4k 1.2× | 798 0.8× | 937 1.4× | 724 1.2× | 41 | 3.3k | |
| Antoine Thiery-Vuillemin | 2.4k 1.3× | 2.0k 1.7× | 985 0.9× | 449 0.7× | 1.2k 2.0× | 155 | 3.7k | |
| Stephen D. Rubin | 1.3k 0.7× | 2.6k 2.2× | 673 0.6× | 811 1.2× | 1.1k 1.9× | 17 | 4.0k | |
| Daniel Petrylak | 1.9k 1.0× | 813 0.7× | 592 0.6× | 726 1.1× | 453 0.8× | 8 | 2.4k | |
| Mary B. Todd | 2.1k 1.2× | 605 0.5× | 691 0.6× | 739 1.1× | 428 0.7× | 54 | 2.5k | |
| Liji Shen | 2.8k 1.5× | 1.3k 1.1× | 946 0.9× | 1.1k 1.7× | 620 1.0× | 37 | 3.5k | |
| Przemyslaw Twardowski | 2.4k 1.3× | 2.2k 1.8× | 1.2k 1.2× | 464 0.7× | 1.6k 2.6× | 113 | 4.3k | |
| Benjamin L. Maughan | 1.4k 0.8× | 915 0.8× | 707 0.7× | 294 0.5× | 541 0.9× | 167 | 2.1k |
Countries citing papers authored by David Lorente
Since
Specialization
Citations
This map shows the geographic impact of David Lorente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lorente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lorente more than expected).
Fields of papers citing papers by David Lorente
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Lorente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lorente. The network helps show where David Lorente may publish in the future.
Co-authorship network of co-authors of David Lorente
This figure shows the co-authorship network connecting the top 25 collaborators of David Lorente. A scholar is included among the top collaborators of David Lorente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lorente. David Lorente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gillessen, Silke, Giuseppe Procopio, Stefanie Hayoz, et al.. (2023). Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). Journal of Clinical Oncology. 41(20). 3608–3615.
2.
Carmona‐Bayonas, Alberto, Raquel Hernández, David Lorente, et al.. (2023). Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer. Clinical & Translational Oncology. 25(12). 3492–3500.
3.
Hernández, Raquel, Ana Fernández Montés, David Lorente, et al.. (2022). Dignity and psychosocial related variables in elderly advanced cancer patients. BMC Geriatrics. 22(1). 732–732.
4.
Suárez, Cristina, Rafael Morales‐Barrera, Joaquı́n Mateo, et al.. (2022). Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Frontiers in Oncology. 12. 970199–970199.
5.
Khasraw, Mustafa, Michael Weller, David Lorente, et al.. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab058–vdab058.
6.
Alba, Aranzazu González del, María José Méndez-Vidal, Elena Castro, et al.. (2021). SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clinical & Translational Oncology. 23(5). 969–979.
7.
Cattrini, Carlo, Alessia Mennitto, Melissa Bersanelli, et al.. (2021). Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. Cancers. 13(18). 4522–4522.
8.
Martín-Liberal, Juan, María Quindós, Almudena García‐Castaño, et al.. (2021). 1088P Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD). Annals of Oncology. 32. S900–S901.
9.
Carretero-González, Alberto, David Lora, Ray Manneh Kopp, et al.. (2020). Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials. Clinical & Translational Oncology. 22(11). 2126–2129.
10.
Cattrini, Carlo, Vincenza Conteduca, María Dolores Martínez Ruiz, et al.. (2020). 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S547–S548.
11.
Domper-Arnal, María José, David Lorente, Regina Gironés Sarrió, et al.. (2020). 640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel. Annals of Oncology. 31. S526–S526.
12.
Juan-Fita, María José, Begoña Mellado, M.J. Méndez Vidal, et al.. (2018). Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response. Annals of Oncology. 29. viii301–viii301.
13.
Coloma, Carmen Salvador, et al.. (2018). P3.08-06 Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors. Journal of Thoracic Oncology. 13(10). S941–S941.
14.
Coloma, Carmen Salvador, David Lorente, Sarai Palanca, et al.. (2018). Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. Journal of Thoracic Disease. 10(3). 1386–1393.
15.
Lorente, David, Praful Ravi, Niven Mehra, et al.. (2016). Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus. 4(2). 235–244.
16.
Rescigno, Pasquale, David Lorente, Diletta Bianchini, et al.. (2016). Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 70(5). 724–731.
17.
Lorente, David, Joaquı́n Mateo, Zafeiris Zafeiriou, et al.. (2015). Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nature Reviews Urology. 12(1). 37–47.
18.
Lorente, David, Joaquı́n Mateo, Arnoud J. Templeton, et al.. (2014). Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Annals of Oncology. 26(4). 750–755.
19.
Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586.
20.
Santaballa, Ana, et al.. (2013). Advantages of one step nucleic acid amplification (OSNA) whole node assay in sentinel lymph node (SLN) analysis in breast cancer. SpringerPlus. 2(1). 542–542.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michael T. Schweizer Breakdown of academic impact, for papers by Ivo Kocák Breakdown of academic impact, for papers by Antoine Thiery-Vuillemin Breakdown of academic impact, for papers by Stephen D. Rubin Breakdown of academic impact, for papers by Daniel Petrylak Breakdown of academic impact, for papers by Mary B. Todd Breakdown of academic impact, for papers by Liji Shen Breakdown of academic impact, for papers by Przemyslaw Twardowski Breakdown of academic impact, for papers by Benjamin L. Maughan